Neurocrine Biosciences
NBIX
#1395
Rank
NZ$21.79 B
Marketcap
$215.25
Share price
0.52%
Change (1 day)
16.79%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2024 (TTM): NZ$1.05 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are NZ$2.24 Billion. In 2023 the company made an earning of NZ$0.61 Billion, an increase over its 2022 earnings that were of NZ$0.37 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) NZ$1.05 B71.59%
2023 NZ$0.61 B62.85%
2022 NZ$0.37 B73.74%
2021 NZ$0.21 B-8.82%
2020 NZ$0.23 B77.78%
2019 NZ$0.13 B49.83%
2018 NZ$89.71 M-142.57%
2017 -NZ$0.22 Billion-14.73%
2016 -NZ$0.25 Billion53.15%
2015 -NZ$0.17 Billion46.25%
2014 -NZ$0.12 Billion29.66%
2013 -NZ$85.11 Million-3530.8%
2012 NZ$2.48 M-95.73%
2011 NZ$58.11 M
2009 -NZ$81.7 Million-45.38%
2008 -NZ$0.15 Billion-58.87%
2007 -NZ$0.37 Billion87.3%
2006 -NZ$0.2 Billion351.97%
2005 -NZ$42.96 Million-52.09%
2004 -NZ$89.66 Million-10.98%
2003 -NZ$0.11 Billion
2001 -NZ$75.18 Million
1999 -NZ$33.91 Million108.32%
1998 -NZ$16.28 Million
1996 NZ$4.96 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
NZ$36.75 M-96.73%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$2.08 B 85.21%๐Ÿ‡ฌ๐Ÿ‡ง UK
-NZ$52.09 Million-104.63%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$17.38 B 1,445.68%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$12.10 B 975.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$2.08 Billion-284.56%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$60.82 M-94.59%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$71.55 Million-106.36%๐Ÿ‡บ๐Ÿ‡ธ USA